ClinicalTrials.gg
CompletedNCT02715024Updated Mar 22, 2016

Study to Evaluate the Clinical Efficacy and Safety of Tamsulosin Alone or in Combination With Solifenacin for the Treatment in Men With Lower Urinary Tract Symptoms Including Overactive Bladder Symptoms

A Phase 4 interventional study of Tamsulosin and Solifenacin in Lower Urinary Tract Symptoms, Overactive Bladder and Benign Prostatic Hyperplasia (BPH), sponsored by Astellas Pharma Taiwan, Inc.. Completed at 1 site in Taiwan. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2016-03-22.

Primary conditionUrinary Bladder, OveractiveRegistry: Lower Urinary Tract SymptomsReclassifiedWhy we changed it
Registry
Lower Urinary Tract Symptoms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Urinary Bladder, Overactive
Why
  1. The study's listed conditions name Urinary Bladder, Overactive, a narrower term within Lower Urinary Tract Symptoms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Astellas Pharma Taiwan, Inc. (part of Astellas Pharma Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 67 studies in Urinary Bladder, Overactive by Astellas Pharma Inc — none open to participants now, none under way, none of them phase 3. Urinary Bladder, Overactive · Astellas Pharma Inc.

Enrollment
38th of 49
52 · median 547
Started
2007
with 2 others
Phase 4
15 of 67
none open now
Registered
61st of 67
by date

Among the 67 studies in Urinary Bladder, Overactive by Astellas Pharma Inc, this one is the 38th largest by enrollment of the 49 interventional ones that give a count, is one of 3 that started in 2007, is one of 15 in phase 4, and was the 61st registered.

Urinary Bladder, Overactive

859 studies on the registry are indexed under Urinary Bladder, Overactive; 126 are open to participants now.

Browse Urinary Bladder, Overactive studies →

Open to participants now

None of the 67 studies in Urinary Bladder, Overactive by Astellas Pharma Inc is open now. The open studies under Urinary Bladder, Overactive, anywhere →

Who these studies take

Of the 73 Urinary Bladder, Overactive studies recruiting now, 44 (60%) set no upper age limit and 15 (21%) stop at 75 or younger; 6 take children under 18; 8 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 67 studies in Urinary Bladder, Overactive by Astellas Pharma Inc as a file.
02

Study summary

The objective of this study is to evaluate the clinical efficacy and safety of tamsulosin alone or in combination with solifenacin for the treatment in men with lower urinary tract symptoms (LUTS) including overactive bladder (OAB) symptoms in Taiwan.

03

Conditions studied

  • Lower Urinary Tract Symptoms
  • Overactive Bladder
  • Benign Prostatic Hyperplasia (BPH)

Browse trials for

Keywords

  • Tamsulosin
  • Solifenacin
  • Lower urinary tract symptoms
  • Overactive bladder
04

In context

Urinary Bladder, Overactive Reclassified

859 studies on the registry are indexed under Urinary Bladder, Overactive; 126 are open to participants now.

This study's enrollment of 52 is below the median of 70 across 649 interventional studies indexed under Urinary Bladder, Overactive.

Browse Urinary Bladder, Overactive studies →

Lead sponsor

Astellas Pharma Taiwan, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.

Compared within Urinary Bladder, Overactive, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lower Urinary Tract Symptoms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical signs and symptoms of frequency and urgency related to benign prostatic hyperplasia for at least 3 months
  • I-PSS(S) score of ≥ 12
  • Maximum flow rate (Qmax) of 4 to15 mL/sec
  • Mean urinary frequency of ≥ 8 micturitions per 24 hours and ≥ 1 episode of urgency per 24 hours as verified by the 3-day micturition diary
  • Benign digital rectal examination (DRE) result

Exclusion criteria

Exclusion Criteria:

  • outflow obstruction
  • Significant post void residue volume (PVR >100ml)
  • Prostate specific antigen (PSA) ≥10 ng/mL
  • Previous or planned prostate surgery, including transurethral resection of the prostate (TURP)
  • Transurethral microwave treatment (TUMT), transurethral needle ablation (TUNA), laser, or other invasive or minimally invasive procedures within 12 months
  • Patient with a neurological cause for abnormal detrusor activity
  • Patients with urinary tract infection, chronic inflammation, bladder stones, bladder neck, sclerosis, urethral stricture, prostatic cancer, severe vesical diverticulum
  • Uncontrolled narrow angle glaucoma, urinary or gastric retention or any other medical condition which in the opinion of the investigator makes the use of anticholinergics
  • Patients with any other complication which may cause voiding dysfunction
  • Patients with severe hepatic dysfunction, severe renal dysfunction, severe cardiovascular disorder, orthostatic hypotension, or senile dementia
  • Patients receiving any medication therapy for LUTS/BPH 2 weeks prior to the study
  • Use of drugs to treat incontinence currently
  • to tamsulosin and/or solifenacin or to any component of the formulation
  • Any clinically significant condition, which in the opinion of the investigator makes the patients unsuitable for the trial
  • Patients had taken any drug in the previous 3 months prior to this study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

06

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Tamsulosin alone

    Drug: Tamsulosin

  • Experimental
    Tamsulosin + solifenacin

    Drug: Tamsulosin · Drug: Solifenacin

Interventions

07

What researchers measure

Primary outcomes

  1. Change in International Prostate Symptoms Score (IPSS-(S)) from baseline to the end of treatment

    Time frame: Baseline and end of treatment (up to 12 weeks)

Secondary outcomes

  1. Change in mean number of urgency episode per 24 hours from baseline to the end of treatment

    Time frame: Baseline and end of treatment (up to 12 weeks)

  2. Change in mean number of micturitions per 24 hours from baseline to the end of treatment

    Time frame: Baseline and end of treatment (up to 12 weeks)

  3. Change in Quality of life index (I-PSS-(L)) from baseline to the end of treatment

    Time frame: Baseline and end of treatment (up to 12 weeks)

  4. Change in maximum flow rate (Qmax) and voided volume determined by uroflowmetry from baseline to the end of treatment

    Time frame: Baseline and end of treatment (up to 12 weeks)

  5. Safety as assessed by adverse events

    Time frame: Up to 12 weeks

  6. Safety as assessed by postvoid residual volume (PVR)

    Measured by bladder scan

    Time frame: Up to 12 weeks

  7. Safety as assessed by vital signs

    Time frame: Up to 12 weeks

  8. Safety as assessed by laboratory parameters

    Time frame: Up to 12 weeks

08

Study locations

1 site
  • Site
    Taipei, Taiwan
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2007, a primary completion of Apr 2011 and a completion of Apr 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 17, 2016
First posted
Mar 22, 2016
Start
Sep 2007
Primary completionActual
Apr 2011
CompletionActual
Apr 2011
Last update
Mar 22, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02715024
Responsible party
Sponsor
First posted
Mar 22, 2016
Start date
Sep 2007
Primary completion
Apr 2011
Completion
Apr 2011
Last update
Mar 22, 2016

Study contacts

Therapeutic Area Lead of Medical Affairs (Asia-Oceania)
study director · Astellas Pharma Taiwan, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tamsulosin

Start the discussion